Precigen’s (PGEN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Precigen (NASDAQ:PGEN) in a report released on Thursday morning,Benzinga reports. They currently have a $6.00 price objective on the biotechnology company’s stock, up from their previous price objective of $4.00. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at ($0.01) EPS, FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.62 EPS.

Separately, JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Up 3.7 %

Shares of Precigen stock opened at $1.39 on Thursday. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93. The company has a market capitalization of $407.09 million, a price-to-earnings ratio of -2.53 and a beta of 1.65. The firm’s 50-day moving average price is $0.94 and its two-hundred day moving average price is $1.06.

Institutional Trading of Precigen

A number of institutional investors have recently bought and sold shares of PGEN. LexAurum Advisors LLC lifted its position in shares of Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock valued at $775,000 after acquiring an additional 417,055 shares during the period. SG Americas Securities LLC raised its position in shares of Precigen by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 12,578 shares during the period. Synovus Financial Corp raised its holdings in shares of Precigen by 100.0% in the 3rd quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 49,065 shares during the last quarter. Barclays PLC lifted its holdings in shares of Precigen by 190.4% in the third quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 124,141 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after acquiring an additional 149,829 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.